Risk Stratification in Luminal Breast Cancer

Dr. Christos Sotiriou presents a case study for luminal breast cancer, discussing the best therapeutic strategies, the importance of genomic tests, and the potential benefits of chemotherapy for different patient profiles.

Target Audience

Healthcare Professionals

Learning Objectives

  • Describe the mechanism of action, pharmacokinetics, and pharmacodynamics of CDK4/6 inhibitors in breast cancer treatment.
  • Review key clinical trial data and regulatory guidelines to understand the placement of CDK4/6 inhibitors in treatment protocols.
  • Recognize the revolutionary results of the introduction of CDK4/6 inhibitors.
  • Understand the differences in efficacy and toxicity profiles among available CDK4/6 inhibitors.

This activity is supported by an educational grant from Eli Lilly.

Course summary

Course opens: 
09/08/2026
Course expires: 
09/30/2031
Cost:
$0.00
Rating: 
0
Dr. Christos Sotiriou

Dr. Christos Sotiriou

Research Director, Fonds de la Recherche Scientifique (FNRS)
Director, Breast Cancer Translational Research Laboratory J-C. Heuson (BCTL), Université Libre de Bruxelles (ULB)
Full Professor, Medical Oncology Department, Institut Jules Bordet (IJB)/Hôpital Universitaire de Bruxelles (HUB)
Director of the Bordet Research Laboratories (BCRL), Institut Jules Bordet (IJB)/Hôpital Universitaire de Bruxelles (HUB)

Price

Cost:
$0.00
Please login or register to take this course.